.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,530,101

« Back to Dashboard

Details for Patent: 5,530,101

Title: Humanized immunoglobulins
Abstract:Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.
Inventor(s): Queen; Cary L. (Los Altos, CA), Selick; Harold E. (Belmont, CA)
Assignee: Protein Design Labs, Inc. (Mountain View, CA)
Filing Date:Dec 19, 1990
Application Number:07/634,278
Claims:1. A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chain frameworks, which humanized immunoglobulin specifically binds to a human interleukin-2 receptor with an affinity constant of at least 10.sup.7 M.sup.-1 and no greater than about two-fold that of the donor immunoglobulin, wherein the sequence of the humanized immunoglobulin heavy chain variable region framework is 65% to 95% identical to the sequence of the donor immunoglobulin heavy chain variable region framework.

2. A humanized immunoglobulin according to claim 1 which is an antibody comprising two light chain/heavy chain dimers.

3. A humanized immunoglobulin according to claim 1, which specifically binds to a human interleukin-2 receptor with an affinity of at least 10.sup.8 M.sup.-1.

4. A humanized immunoglobulin according to claim 1, wherein said human interleukin-2 receptor is the p55 Tac interleukin-2 receptor.

5. A humanized immunoglobulin according to claim 1, wherein said human interleukin-2 receptor is the p75 interleukin-2 receptor.

6. A humanized immunoglobulin according to claim 1, wherein said donor immunoglobulin is the anti-Tac antibody.

7. A humanized immunoglobulin according to claim 1, wherein said acceptor immunoglobulin heavy and light chain frameworks are from the same human antibody.

8. A humanized immunoglobulin according to claim 7, wherein said human antibody is the Eu human antibody.

9. A humanized immunoglobulin according to claim 1 which is substantially pure.

10. A humanized immunoglobulin according to claim 1 that competitively inhibits the binding of interleukin-2 to said human interleukin-2 receptor.

11. A recombinant immunoglobulin which specifically binds to the p55 chain of the human IL-2 receptor, wherein the amino acid sequence of the mature light chain variable region is: ##STR1##

12. A recombinant immunoglobulin which specifically binds to the p55 chain of the human IL-2 receptor, wherein the amino acid sequence of the mature heavy chain variable region is: ##STR2##

13. An immunoglobulin which specifically binds to the p55 chain of the human IL-2 receptor, said immunoglobulin having two pairs of heavy and light chains wherein:

each light chain comprises a complete human kappa chain constant region sequence and a variable region sequence: ##STR3## and each heavy chain comprises a complete human .gamma. chain constant region sequence and a variable region sequence: ##STR4##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc